Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.44 |
| ▸ | CA2 | P00918 | 4/20 | 0.44 |
| ▸ | CA7 | P43166 | 3/20 | 0.44 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 2/20 | 0.39 |
| ▸ | CA6 | P23280 | 2/20 | 0.39 |
| ▸ | CA5A | P35218 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NT5E | P21589 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26864 | 0.96 | — | — | |
| SCHEMBL28241435 | 0.96 | CA1 (0.47) | CA1CA2CA7CA13CA4 | |
| SCHEMBL28300896 | 0.92 | — | — | |
| SCHEMBL30656011 | 0.92 | CA1 (0.44) | CA1CA2CA7CA13CA4 | |
| Hydrochloric Acid SCHEMBL10876127 | 0.92 | — | — | |
| Sulfamide SCHEMBL25410596 | 0.92 | CA1 (0.50) | CA1CA2CA7CA13CA4 | |
| SCHEMBL28257688 | 0.92 | — | — | |
| Methane SCHEMBL29135581 | 0.88 | CA1 (0.41) | CA1CA2CA7CA13CA4 | |
| Benzene SCHEMBL9326550 | 0.85 | CA1 (0.40) | CA1CA2CA7CA13CA4 | |
| Butane SCHEMBL27918070 | 0.82 | CA1 (0.42) | CA1CA2CA7CA13CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1745032-B1 | CXCR1 and CXCR2 chemokine antagonists | MERCK SHARP & DOHME (US) | 2013-07-31 | — | — | EP | disclosed |
| US-7326729-B2 | CXCR1 and CXCR2 chemokine antagonists | SCHERING CORPORATION (US) | 2008-02-05 | — | — | US | disclosed |
| US-20070248594-A1 | CXCR1 AND CXCR2 CHEMOKINE ANTAGONISTS | SCHERING CORPORATION | 2007-10-25 | — | — | US | disclosed |
| EP-1745032-A2 | CXCR1 AND CXCR2 CHEMOKINE ANTAGONISTS | Schering Cooperation (US) | 2007-01-24 | — | — | EP | disclosed |
| US-20060014794-A1 | CXCR1 and CXCR2 chemokine antagonists | SCHERING CORPORATION | 2006-01-19 | — | — | US | disclosed |
| WO-2005113534-A2 | CXCR1 AND CXCR2 CHEMOKINE ANTAGONISTS | SCHERING CORPORATION (US) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070248594-A1 | CXCR1 AND CXCR2 CHEMOKINE ANTAGONISTS | CXCR1, CXCR2, CXCR5 | CA1 2319/4885CA2 2801/4885CA7 2490/4885 |
| US-20060014794-A1 | CXCR1 and CXCR2 chemokine antagonists | CXCR1, CXCR2, CXCR5 | CA1 2319/4885CA2 2801/4885CA7 2490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.